Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis-Reference-Cited by-同舟云学术

Safety of Janus Kinase Inhibitors in Patients With Inflammatory Bowel Diseases or Other Immune-mediated Diseases: A Systematic Review and Meta-Analysis

Published:2020-05 Issue:6 Volume:158 Page:1554-1573.e12
ISSN:0016-5085
Container-title:Gastroenterology
language:en
Short-container-title:Gastroenterology

Author:

Olivera Pablo A.,Lasa Juan S.,Bonovas Stefanos^ORCID,Danese Silvio,Peyrin-Biroulet Laurent

Funder

Pfizer

Publisher

Elsevier BV

Subject

Gastroenterology,Hepatology

Reference104 articles.

1. Crohn’s disease;Torres;Lancet,2016

2. Ulcerative colitis;Ungaro;Lancet,2017

3. Biologic agents for IBD: practical insights;Danese;Nat Rev Gastroenterol Hepatol,2015

4. JAK inhibition in inflammatory bowel disease;Olivera;Expert Rev Clin Immunol,2017

5. Next generation of small molecules in inflammatory bowel disease;Olivera;Gut,2017

Cited by 218 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of nonmelanoma skin cancer in patients taking Janus kinase inhibitors for inflammatory bowel disease: A systematic review and meta-analysis;Dermatologica Sinica;2024-09-04

2. Tofacitinib for the treatment of immune-related adverse events in cancer immunotherapy: a multi-center observational study;Journal of Translational Medicine;2024-08-29

3. Small Molecule Therapy for Inflammatory Bowel Disease: JAK Inhibitors and S1PR Modulators;The Korean Journal of Gastroenterology;2024-08-25

4. Small Bowel Cancer in Crohn’s Disease;Cancers;2024-08-21

5. Extraintestinal Manifestations in Inflammatory Bowel Disease: From Pathophysiology to Treatment;Biomedicines;2024-08-13